Alzamend Neuro Overview
- Founded
-
2016
- Status
-
Public
- Employees
-
8
- Stock Symbol
-
ALZN
- Share Price
-
$1.08
- (As of Friday Closing)
Alzamend Neuro General Information
Description
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
Contact Information
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
- 3802 Spectrum Boulevard
- Suite 112C
- Tampa, FL 33612
- United States
+1 (844) 000-0000
Alzamend Neuro Timeline
Alzamend Neuro Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.08 | $1.21 | $0.80 - $3.57 | $116M | 95.5M | 464K | -$0.15 |
Alzamend Neuro Financials Summary
|
In Thousands, USD |
TTM 31-Jul-2022 | FY 2022 30-Apr-2022 | FY 2021 30-Apr-2021 | FY 2020 30-Apr-2020 |
|---|---|---|---|---|
| EV | 70,829 | 83,089 | ||
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (13,045) | (12,312) | (4,889) | (4,424) |
| Net Income | (13,079) | (12,362) | (5,047) | (4,410) |
| Total Assets | 12,210 | 14,516 | 2,913 | 1,814 |
| Total Debt | 0 | 0 | 335 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Alzamend Neuro Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Alzamend Neuro Executive Team (5)
Alzamend Neuro Board Members (6)
| Name | Representing | Role | Since |
|---|---|---|---|
| Henry Nisser | Self | Board Member & Executive Vice President | 000 0000 |
| Mark Gustafson | Self | Board Member | 000 0000 |
| Milton Ault III | Self | Chairman & Board Member | 000 0000 |
| Philip Mansour | Alzamend Neuro | Board Member | 000 0000 |
| Stephan Jackman | Alzamend Neuro | Chief Executive Officer & Board Member | 000 0000 |
Alzamend Neuro Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Alzamend Neuro Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|